Research records indexed for Survodutide
This page carries 12 of the 90 records that the literature query returned for Survodutide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 78 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Survodutide.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Survodutide Once Weekly for the Treatment of Adults with Obesity pmid:42253238 | 2026 | Clinical Trial, Phase III, Multicenter Study | human trial | Not stated | Indexed as clinical trial, phase iii, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Obesity; Weight Loss; Receptors, Glucagon; Anti-Obesity Agents; Drugs, Investigational. |
| Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial pmid:42252333 | 2026 | Clinical Trial, Phase III, Randomized Controlled Trial | human trial | Not stated | Indexed as clinical trial, phase iii, randomized controlled trial. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Liver; Fatty Liver; Obesity; Magnetic Resonance Imaging; Body Mass Index. |
| Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes pmid:41216778 | 2026 | Clinical Trial, Phase III, research-article | human trial | Not stated | Indexed as clinical trial, phase iii, research-article. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Obesity; Weight Loss; Receptors, Glucagon; Anti-Obesity Agents. |
| Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1) pmid:41187967 | 2026 | Clinical Trial, Phase III, research-article | human trial | Not stated | Indexed as clinical trial, phase iii, research-article. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Obesity; Weight Loss; Anti-Obesity Agents; Injections, Subcutaneous. |
| Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity pmid:42331726 | 2026 | Clinical Trial, Phase II, research-article | human trial | Not stated | Indexed as clinical trial, phase ii, research-article. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: Diabetes Mellitus, Type 2; Insulin Resistance; Obesity; Metformin; Glucagon. |
| Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial pmid:42219222 | 2026 | Clinical Trial Protocol, methods-article | other | Not stated | Indexed as clinical trial protocol, methods-article. study model from MeSH "Humans" with no interventional publication type. subject headings: Diabetes Mellitus, Type 2; Obesity; Weight Loss; Anti-Obesity Agents; Japan. |
| A review of survodutide: a new dual acting agonist pmid:41855048 | 2026 | Review | other | Not stated | Indexed as review. study model from MeSH "Animals" with no rodent species heading. subject headings: Diabetes Mellitus, Type 2; Obesity; Somatostatin; Receptors, Glucagon; Hypoglycemic Agents. |
| Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation pmid:41638399 | 2026 | research-article | rodent | Not stated | Indexed as research-article. study model from MeSH "Mice, Inbred C57bl". subject headings: Brain; Area Postrema; Hypothalamus; Neurons; Mice, Inbred C57BL. |
| Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2) pmid:39495965 | 2025 | Clinical Trial Protocol, research-article | other | Not stated | Indexed as clinical trial protocol, research-article. study model from MeSH "Humans" with no interventional publication type. subject headings: Diabetes Mellitus, Type 2; Obesity; Body Weight; Weight Loss; Glucagon. |
| Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m<sup>2</sup> in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist pmid:39821928 | 2025 | Clinical Trial, Phase II, research-article | human trial | Not stated | Indexed as clinical trial, phase ii, research-article. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: Obesity; Hypoglycemic Agents; Body Mass Index; Sex Factors; Waist Circumference. |
| Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide pmid:40619099 | 2025 | research-article | rodent | Not stated | Indexed as research-article. study model from MeSH "Mice, Inbred C57bl". subject headings: Mice, Inbred C57BL; Obesity; Peptide YY; Receptors, Neuropeptide Y; Anti-Obesity Agents. |
| Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis pmid:40922121 | 2025 | Meta-Analysis, Systematic Review | other | Not stated | Indexed as meta-analysis, systematic review. study model from MeSH "Humans" with no interventional publication type. subject headings: Diabetes Mellitus, Type 2; Weight Loss; Blood Glucose; Hypoglycemic Agents; Randomized Controlled Trials As Topic. |
Where this page sits
Compound page: Survodutide. Class: Incretin receptor agonists.
Retrieved 2026-10-12.
Sources
- PubChem Compound Summary for CID 171378821, survodutide. PubChem, National Library of Medicine (2026). pubchem:171378821
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:survodutide
- BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Molecular metabolism (2022). pmid:36356832
- Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, obesity & metabolism (2023). pmid:36527386
- A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity. Diabetes, obesity & metabolism (2023). pmid:36974349
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The lancet. Diabetes & endocrinology (2024). pmid:38330987
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. The New England journal of medicine (2024). pmid:38847460
- Dose-response effects on HbA<sub>1c</sub> and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia (2024). pmid:38095657
- Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. Journal of hepatology (2024). pmid:38857788
- Survodutide Once Weekly for the Treatment of Adults with Obesity. The New England journal of medicine (2026). pmid:42253238
- Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2). Obesity (Silver Spring, Md.) (2025). pmid:39495965
- Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial. JACC. Heart failure (2024). pmid:39453356
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.